8-K: Rallybio Announces 1-for-2 Reverse Stock Split Ahead of Merger

Rallybio Corporation is implementing a one-for-two reverse stock split, effective November 20, 2026, in preparation for its merger with Avenzo Therapeutics, Inc., after which the combined entity will be renamed Avenzo Therapeutics, Inc. and trade under the symbol AVZO.

Summary

• Rallybio Corporation announced a one-for-two reverse stock split of its common stock, effective November 20, 2026.
• This action is in connection with the Agreement and Plan of Merger and Reorganization with Avenzo Therapeutics, Inc.
• The reverse stock split will reduce the number of outstanding shares from approximately 5.6 million to 2.8 million before the merger.
• Following the merger and Nasdaq approvals, the company will change its name to Avenzo Therapeutics, Inc. and trade under the symbol AVZO.
• Fractional shares will be settled with cash payments based on the closing price on the effective date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly negative development, as reverse stock splits are often undertaken to meet exchange listing requirements or to increase the stock price, which can signal underlying challenges.

Positives

• The reverse stock split is a necessary step to facilitate the merger with Avenzo Therapeutics, which is expected to bring new product candidates.
• The merger and subsequent name change to Avenzo Therapeutics, Inc. signal a strategic shift and potential for future growth in oncology therapies.

Negatives

• Reverse stock splits are often implemented to boost a low stock price and meet exchange listing requirements, which can be a sign of past underperformance.
• The need for a reverse split may indicate that the company's stock price has fallen significantly, potentially impacting investor confidence.

Risks

• The risk that the Merger will be delayed or not completed due to unsatisfied closing conditions, including Nasdaq listing approvals.
• The risk that events could lead to the termination of the Merger Agreement.
• Delays in implementing the reverse stock split or commencing split-adjusted trading.
• The risk that the reverse stock split will not result in a sustained increase in the trading price of the common stock or ensure compliance with Nasdaq listing requirements.
• Risks associated with the development and commercialization of product candidates from both Rallybio and Avenzo.

Future Outlook

The company anticipates completing the merger with Avenzo Therapeutics, Inc., changing its name to Avenzo Therapeutics, Inc., and trading under the new symbol AVZO on the Nasdaq Capital Market following the reverse stock split and satisfaction of closing conditions. The combined entity will focus on developing and commercializing oncology therapies.

Management Comments

• The reverse stock split is expected to become effective at 12:01 a.m., Eastern Time, on November 20, 2026, prior to the anticipated completion of the merger contemplated by the Merger Agreement.
• Following the satisfaction of applicable Nasdaq approvals and the closing of the Merger, the Company plans to change its name to Avenzo Therapeutics, Inc. and to trade on the Nasdaq Capital Market under the new trading symbol AVZO and the new CUSIP number 053928 107.

Industry Context

StockSavvy.ai notes that reverse stock splits are common in the biotechnology sector, particularly for clinical-stage companies, as a means to maintain compliance with exchange listing requirements and potentially improve the stock's marketability. The merger with Avenzo Therapeutics, which has a pipeline focused on oncology, indicates a strategic consolidation within the competitive biotech landscape.

Stakeholder Impact

• Shareholders will see their number of shares halved, with fractional shares being cashed out, though their percentage ownership will remain the same unless they hold fractional shares.
• The reverse stock split and merger are intended to improve the company's market position and potential for future growth, which could benefit shareholders.
• The change in trading symbol and company name will affect how investors identify and track the company's performance.

Next Steps

• Effect the one-for-two reverse stock split on November 20, 2026.
• Complete the merger with Avenzo Therapeutics, Inc.
• Change the company name to Avenzo Therapeutics, Inc.
• Begin trading on the Nasdaq Capital Market under the new symbol AVZO.

Key Dates

Recommendation

The reverse stock split is a procedural step for a merger, and the future value will depend on the success of Avenzo's pipeline. While the merger itself is a positive strategic move, the need for a reverse split suggests past stock price weakness. Therefore, a 'hold' recommendation is appropriate pending further developments and clinical trial results of the combined entity.

Keywords

reverse stock split, merger, Avenzo Therapeutics, biotechnology, oncology therapies, Nasdaq, stockholder approval, clinical-stage